Want to see SNGX full AI Analyst Report?
Top Page
Soligenix
(NASDAQ:SNGX)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.34
▼(-11.58% Downside)
Action:Reiterated
Date:08/18/26
The score is primarily held down by weak financial performance (pre-revenue, sizable losses, and ongoing cash burn implying continued funding needs). Technicals remain unfavorable on longer-term trend measures, and valuation is constrained by negative earnings. The latest corporate developments add meaningful risk due to both delisting pressure and a significant program termination.
Positive Factors
Low leverage
Modest leverage and rebuilt equity provide some financial flexibility compared with the company’s earlier stressed capital structure. A relatively low debt burden can reduce fixed obligations and preserve more options for funding clinical development, although operating losses remain substantial.
Negative Factors
Pre-revenue business model
The absence of meaningful revenue means Soligenix has not yet demonstrated a commercial model capable of funding operations. Persistent and widening losses increase dependence on future financing or successful product development, making profitability and earnings visibility weak over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage
Modest leverage and rebuilt equity provide some financial flexibility compared with the company’s earlier stressed capital structure. A relatively low debt burden can reduce fixed obligations and preserve more options for funding clinical development, although operating losses remain substantial.
Read all positive factors
Soligenix (SNGX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$7.62M
Dividend YieldN/A
Average Volume (3M)201.91K
Price to Earnings (P/E)―
Beta (1Y)0.25
Revenue GrowthN/A
EPS Growth66.94%
CountryUS
Employees14
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.27
Shares Outstanding21,765,478
10 Day Avg. Volume133,881
30 Day Avg. Volume201,906
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.31
Price to Sales (P/S)0.00
P/FCF Ratio-0.68
Enterprise Value/Market Cap-0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.52K
Enterprise Value/Ebitda0.29
Forecast
1Y Price Target
$1.50Price Target Upside294.74% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.4
Revenue Forecast (FY)N/A
Soligenix Business Overview & Revenue Model
Company Description
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two mai...
Soligenix Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
52
Neutral
Cash Flow
12
Very Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 250.00K | 33.35K |
| Gross Profit | -2.10K | 0.00 | -119.37K | -742.05K | -300.82K | -695.29K |
| EBITDA | -10.92M | -11.58M | -9.46M | -7.67M | -14.11M | -12.48M |
| Net Income | -10.24M | -11.08M | -8.27M | -6.14M | -13.80M | -12.55M |
Balance Sheet | ||||||
| Total Assets | 10.50M | 9.24M | 8.97M | 9.80M | 14.28M | 26.87M |
| Cash, Cash Equivalents and Short-Term Investments | 9.81M | 7.94M | 7.82M | 8.45M | 13.36M | 26.04M |
| Total Debt | 302.59K | 358.14K | 1.48M | 3.49M | 10.24M | 9.96M |
| Total Liabilities | 3.85M | 3.94M | 4.85M | 7.27M | 16.75M | 16.15M |
| Stockholders Equity | 6.65M | 5.29M | 4.12M | 2.52M | -2.47M | 10.72M |
Cash Flow | ||||||
| Free Cash Flow | -9.74M | -10.27M | -8.40M | -8.60M | -12.66M | -11.75M |
| Operating Cash Flow | -9.74M | -10.27M | -8.40M | -8.60M | -12.65M | -11.74M |
| Investing Cash Flow | -2.57K | -5.88K | 0.00 | 0.00 | -13.07K | -11.79K |
| Financing Cash Flow | 14.46M | 10.39M | 7.76M | 3.66M | 76.82K | 19.06M |
Soligenix Technical Analysis
Negative
0.38
Price Trends
0.37
Negative
0.38
Negative
0.70
Negative
Market Momentum
>-0.01
Negative
45.86
Neutral
66.67
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNGX, the sentiment is Negative. The current price of 0.38 is above the 20-day moving average (MA) of 0.35, above the 50-day MA of 0.37, and below the 200-day MA of 0.70, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.86 is Neutral, neither overbought nor oversold. The STOCH value of 66.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SNGX.
Soligenix Risk Analysis
Soligenix disclosed 47 risk factors in its most recent earnings report. Soligenix reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Soligenix Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $9.68M | -1.05 | -47.22% | ― | -91.94% | 55.29% | |
42 Neutral | $7.62M | -0.28 | -181.02% | ― | ― | 66.94% | |
42 Neutral | $5.78M | -0.31 | -217.50% | ― | -87.73% | 51.12% | |
40 Underperform | $5.48M | -0.26 | -182.88% | ― | ― | ― | |
40 Underperform | $1.96M | -0.01 | -743.66% | ― | -100.00% | 77.63% |
* Healthcare Sector Average
SNGX
Soligenix
0.36
-1.20
-76.73%
BLRX
Bioline RX Ltd Sponsored ADR
2.03
-1.65
-44.84%
CANF
Can-Fite BioPharma
1.65
-7.57
-82.10%
GOVX
GeoVax Labs
0.20
-14.78
-98.66%
AIMD
Ainos
0.79
-2.83
-78.07%
Soligenix Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingRegulatory Filings and ComplianceShareholder MeetingsStock Split
Soligenix Shareholders Approve Governance and Capital Changes
Neutral
Sep 21, 2026
At its Annual Meeting on September 17, 2026, Soligenix shareholders elected five directors to serve until the 2027 meeting and approved several corporate governance and capital structure measures. Investors backed a potential reverse stock split a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.